These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12949542)

  • 1. Roche and Igen in shotgun wedding.
    Bouchie A
    Nat Biotechnol; 2003 Sep; 21(9):958. PubMed ID: 12949542
    [No Abstract]   [Full Text] [Related]  

  • 2. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 3. Amgen's Japan deal.
    Ratner M
    Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392006
    [No Abstract]   [Full Text] [Related]  

  • 4. GlaxoSmithKline, Pfizer to merge HIV drug units in new company.
    AIDS Read; 2009; 19(6):206. PubMed ID: 19642236
    [No Abstract]   [Full Text] [Related]  

  • 5. Sugen falls as casualty of Pfizer-Pharmacia merger.
    Garber K
    Nat Biotechnol; 2003 Jul; 21(7):722-3. PubMed ID: 12833079
    [No Abstract]   [Full Text] [Related]  

  • 6. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 7. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 8. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 9. A license to print money?
    Nat Biotechnol; 2006 Jun; 24(6):593. PubMed ID: 16763570
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 11. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 12. Licensing deals morph to acquisitions in seller's market.
    Moran N
    Nat Biotechnol; 2007 Jun; 25(6):609-10. PubMed ID: 17557085
    [No Abstract]   [Full Text] [Related]  

  • 13. Genomics companies shop around for chemical expertise.
    Fletcher L
    Nat Biotechnol; 2004 Feb; 22(2):137-8. PubMed ID: 14755277
    [No Abstract]   [Full Text] [Related]  

  • 14. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 15. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 16. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 17. Genentech makes its first-ever acquisition.
    Hollmer M
    Nat Biotechnol; 2007 Jan; 25(1):4-5. PubMed ID: 17211375
    [No Abstract]   [Full Text] [Related]  

  • 18. Goodbye Columbus! New NRDOs forego discovery.
    Thiel KA
    Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
    [No Abstract]   [Full Text] [Related]  

  • 19. Not for the chicken-hearted.
    Nat Biotechnol; 2006 Aug; 24(8):870. PubMed ID: 16900108
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotech firms jump on SARS bandwagon.
    Basu P
    Nat Biotechnol; 2003 Jul; 21(7):720. PubMed ID: 12833076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.